Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.

Fransen S, Gupta S, Frantzell A, Petropoulos CJ, Huang W.

J Virol. 2012 Jul;86(13):7249-55. doi: 10.1128/JVI.06618-11. Epub 2012 May 2.

2.
3.

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.

Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, Huang W.

J Virol. 2009 Nov;83(22):11440-6. doi: 10.1128/JVI.01168-09. Epub 2009 Sep 16.

4.

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF.

Retrovirology. 2011 Aug 19;8:68. doi: 10.1186/1742-4690-8-68.

5.

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA.

J Virol. 2014 Sep 1;88(17):9683-92. doi: 10.1128/JVI.00947-14. Epub 2014 Jun 11.

7.

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, Clementi M.

J Antimicrob Chemother. 2010 Mar;65(3):425-33. doi: 10.1093/jac/dkp477. Epub 2010 Jan 7.

PMID:
20056687
8.

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M.

J Antimicrob Chemother. 2013 Nov;68(11):2525-32. doi: 10.1093/jac/dkt220. Epub 2013 Jun 24.

PMID:
23798668
9.

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R.

Virology. 2010 Jul 5;402(2):338-46. doi: 10.1016/j.virol.2010.03.034. Epub 2010 Apr 24.

10.

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.

Nguyen TT, Rato S, Molina JM, Clavel F, Delaugerre C, Mammano F.

J Antimicrob Chemother. 2015 Mar;70(3):731-8. doi: 10.1093/jac/dku424. Epub 2014 Oct 21.

PMID:
25336162
11.

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.

Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF.

Antimicrob Agents Chemother. 2010 Jan;54(1):491-501. doi: 10.1128/AAC.01075-09. Epub 2009 Nov 9.

12.

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.

14.

HIV-1 Group O Resistance Against Integrase Inhibitors.

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):9-15. doi: 10.1097/QAI.0000000000000698.

PMID:
26017662
15.

Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.

Hu Z, Kuritzkes DR.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):148-55. doi: 10.1097/QAI.0b013e3181e9a87a.

16.

Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

Métifiot M, Maddali K, Naumova A, Zhang X, Marchand C, Pommier Y.

Biochemistry. 2010 May 4;49(17):3715-22. doi: 10.1021/bi100130f.

17.

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.

Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N.

AIDS. 2009 Feb 20;23(4):455-60. doi: 10.1097/QAD.0b013e328323da60.

PMID:
19165083
18.

Evolution of raltegravir resistance during therapy.

Sichtig N, Sierra S, Kaiser R, Däumer M, Reuter S, Schülter E, Altmann A, Fätkenheuer G, Dittmer U, Pfister H, Esser S.

J Antimicrob Chemother. 2009 Jul;64(1):25-32. doi: 10.1093/jac/dkp153. Epub 2009 May 14.

PMID:
19447792
19.

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2009 Apr;63(4):795-804. doi: 10.1093/jac/dkp014. Epub 2009 Feb 16.

PMID:
19221102
20.

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F.

J Infect Dis. 2012 Feb 15;205(4):557-67. doi: 10.1093/infdis/jir821. Epub 2012 Jan 11.

Supplemental Content

Support Center